Tag Archives: (GMAB)

The Anti-Biotech Biotech

I was grabbing coffee with my old Marine buddy Mike last week when he asked me about biotech stocks. “John,” he said, “every time I buy one of these pharmaceutical companies, it’s like stepping on an IED. What am I missing?” I laughed because Mike’s not wrong. The biotech sector has been a graveyard for […]

Shaken, Not Stirred

Did you know the antibody behind Johnson & Johnson’s (JNJ) blockbuster cancer drug Darzalex was actually developed by a small Danish biotech most investors have never heard of? That biotech is Genmab (GMAB), and they’re like the secret agent of the biotech world — operating in the shadows while their technology powers some of the […]